Efficacy, Safety and Response Predictors of Astragalus Membranaceus on the Improvement of Cognitive Function in Mild-to-Moderate Alzheimer's Disease

NCT05578443 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: 10g Astragalus
BEHAVIORAL: Routine treatment
DRUG: 20g Astragalus

Sponsor

Fujian Medical University Union Hospital